The c.1601_1602del (p.Tyr534CysfsTer82) variant in GP1BA is a frameshift variant that may cause a premature stop codon that is predicted to escape nonsense mediated decay, however it alters a functionally important region, the transmembrane domain (amino acids 532-553), in a gene where loss-of-function is an established disease mechanism (PVS1_Strong). At least one patient (Patient 1 in PMID: 9326230) with this variant had less than 10% expression of GPIba measured by Western blot, which is highly specific for Bernard-Soulier syndrome. The patient also had a severe defect in ristocetin agglutination and a life-long history of excessive bleeding (PP4). This variant has been detected in at least three probands with Bernard-Soulier syndrome. Two of these individuals were homozygous for the variant (PMIDs: 9326229 and 9326230) and one individual was compound heterozygous (confirmed in trans by parental testing) for this variant and the c.165_168del (p.Ser55ArgfsTer12) which was classified as Likely Pathogenic by the VCEP (PMID: 11054083) (PM3_Strong). Surface expression of GP1a measured by flow cytometry in CHO βIX cells transiently co-transfected with the c.1601_1602del variant GP1 and wild type GP1a showed decreased expression at 20% (<25%) WT levels, indicating that this variant impacts protein function (PMID: 9326230)(PS3_supporting). The Grpmax Filtering allele frequency in gnomAD v4.1.0 is 0.00002394 (based on 38/1179788 alleles) in the European non-Finnish population, which is lower than the ClinGen PD VCEP threshold (<0.0001114; PM2_Supporting). In summary, this variant meets the criteria to be classified as Pathogenic for autosomal recessive Bernard-Soulier syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen PD VCEP: PVS1_Strong, PM3_Strong, PP4, PM2_Supporting and PS3_Supporting (VCEP specifications version 1).